- Home
- CANF vs PHIO Comparison
CANF vs PHIO Comparison
Compare CANF & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- PHIO
- Stock Information
- Founded
- CANF 1994
- PHIO 2011
- Country
- CANF Israel
- PHIO United States
- Employees
- CANF N/A
- PHIO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- PHIO Health Care
- Exchange
- CANF Nasdaq
- PHIO Nasdaq
- Market Cap
- CANF 9.6M
- PHIO 10.5M
- IPO Year
- CANF N/A
- PHIO N/A
- Fundamental
- Price
- CANF $0.63
- PHIO $1.97
- Analyst Decision
- CANF Strong Buy
- PHIO Strong Buy
- Analyst Count
- CANF 2
- PHIO 3
- Target Price
- CANF $14.00
- PHIO $10.67
- AVG Volume (30 Days)
- CANF 140.0K
- PHIO 133.0K
- Earning Date
- CANF 08-26-2025
- PHIO 08-14-2025
- Dividend Yield
- CANF N/A
- PHIO N/A
- EPS Growth
- CANF N/A
- PHIO N/A
- EPS
- CANF N/A
- PHIO N/A
- Revenue
- CANF $560,000.00
- PHIO N/A
- Revenue This Year
- CANF $461.72
- PHIO N/A
- Revenue Next Year
- CANF N/A
- PHIO N/A
- P/E Ratio
- CANF N/A
- PHIO N/A
- Revenue Growth
- CANF N/A
- PHIO N/A
- 52 Week Low
- CANF $0.63
- PHIO $0.97
- 52 Week High
- CANF $3.12
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- CANF 29.23
- PHIO 35.02
- Support Level
- CANF $0.64
- PHIO $1.99
- Resistance Level
- CANF $0.68
- PHIO $2.07
- Average True Range (ATR)
- CANF 0.03
- PHIO 0.12
- MACD
- CANF 0.01
- PHIO -0.01
- Stochastic Oscillator
- CANF 2.00
- PHIO 16.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.